ADX71149 for the treatment of epilepsy.
Our partnered drug candidate, ADX71149 is a novel orally active mGlu2 PAM for the treatment of epilepsy. Our partner, Janssen Pharmaceuticals, Inc., or Janssen, a subsidiary of Johnson & Johnson is conducting a placebo- controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021. We expect to report topline results in the fourth quarter of 2022.
Under our agreement with Janssen, Janssen is responsible for financing the development and commercialization, if any, of ADX71149.